Our xTAG® and MultiCode™-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.
Read More
Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.
Read More
Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
Learn More
Luminex Licensed Technologies Partner Spotlight: Radix BioSolutions
Custom assay development
At Radix, scientists design and manufacture Luminex assays so their customers can focus on what they’re really interested in: the results. The company is one of our Licensed Technologies Partners, a group that includes a wide range of markets, organization types, and locations. All of the Licensed Technologies Partners conduct work that is powered by Luminex’s versatile xMAP® Technology, which has supported the launch of thousands of multiplexed immunoassays as the basis for commercially available kits and testing services.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
Watch more videos >
August 6
Luminex Corporation Reports Second Quarter 2018 Financial Results
July 13
Luminex Corporation Second Quarter Earnings Release Scheduled for August 6, 2018
June 13
Luminex Initiates Clinical Trials for VERIGENE® II Gastrointestinal Assay
May 18
Luminex Corporation to Present at Upcoming Healthcare Investor Conferences
May 18
Luminex Corporation Declares Second Quarter Cash Dividend
ECI
2-5 September
Amsterdam, Netherlands
Microbe UK
21-23 September
Sheffield, UK
World Vaccine Congress
29-31 October
Lisbon, Portugal
xMAP® Connect Amsterdam
6-7 November
Amsterdam, Netherlands
